Provided by Tiger Fintech (Singapore) Pte. Ltd.

NGM Biopharmaceuticals Inc

1.54
+0.0000
Volume:- -
Turnover:3.70M
Market Cap:128.53M
PE:-0.89
High:1.54
Open:1.54
Low:1.54
Close:1.54
Loading ...
Feb 24, 2020

Major Issues Report

Current report, items 8.01 and 9.01
Feb 13, 2020

Major Issues Report

Current report, item 5.02
Feb 11, 2020

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
Jan 13, 2020

Major Issues Report

Current report, items 7.01 and 9.01
Dec 05, 2019

Major Issues Report

Current report, item 5.02
Nov 26, 2019

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
Nov 12, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Nov 12, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Oct 18, 2019

Beneficial Ownership Change

[Amend] General statement of acquisition of beneficial ownership
Oct 07, 2019

Major Issues Report

Current report, items 8.01 and 9.01
Aug 12, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Aug 12, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Aug 09, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Aug 09, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Aug 09, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Aug 07, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Aug 07, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Aug 07, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Aug 05, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Aug 05, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities